35 results about "Brown Adipocytes" patented technology

Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and / or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and / or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and / or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and / or systemically to stimulate the nerves and / or the brown adipocytes.

Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and / or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.

Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and / or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.

Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and / or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of, or the making of medicaments for the treatment of, metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia.

Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.

A method for converting animal cells into brown adipose tissue cells is provided that includes transforming the animal cells using an expression vector. The expression vector includes a nucleotide sequence encoding HB-EGF operatively linked to a promoter and a nucleotide sequence encoding ADAM 12 operatively linked to a promoter. Converting animal cells to brown adipose tissue cells can be used to treat obesity or to treat cancer by converting target cells to brown adipose tissue cells.

Methods of generating functional human brown adipocytes, comprising exposing human stem cells, progenitor cells, or white adipocytes to culture with an differentiation cocktail that comprises one or more browning agents (e.g., one or more macromolecular crowders), and optionally one or more adipogenic agents, are described, as are populations of human brown adipocytes generated by the methods, and uses for the populations. Methods of generating functional human brown adipocytes in an individual, such as by administering a pharmaceutical composition comprising an differentiation cocktail, are also described.

The present invention provides an application of a thermogenesis-enhancing compound to enhance the thermogenesis induced by a norepinephrine compound in brown adipocytes. Specifically, the present invention provides a use of a thermogenesis-enhancing compound for preparing a preparation or a composition. The preparation or composition is used to enhance the heat production efficiency of brown fat cells induced by NE compounds, wherein the heat production enhancing compound is selected from the group consisting of ATP compounds, ATP synthase inhibitors, or combinations thereof. The heat production enhancing compound of the present invention can significantly enhance the heat production efficiency of brown fat cells induced by norepinephrine compounds.

The application of butylenephthalide (butylidenephthalide, BP) includes using butylenephthalide (BP) to provide a kind of kit for promoting the differentiation of stem cells into brown adipocytes, and using butylenephthalide (BP) in the manufacture of A use of a medicament, wherein the medicament is used for inhibiting the accumulation of white fat, promoting the transformation of white fat into brown fat, inhibiting weight gain and / or reducing the content of triglyceride, glucose and total cholesterol in blood.

Provided is a composition that comprises a supernatant of brown adipocytes or a purified product thereof and has a metabolism improving effect. Also provided is a method for preparing the aforesaid supernatant without using a liquid culture containing glucose at a high concentration. Also provided is a method for producing brown adipocytes using pluripotent stem cells, said method being useful for preparing a supernatant of brown adipocytes. In the present invention, a supernatant having a metabolism improving effect was successfully obtained from brown adipocytes. Also, this supernatant could be obtained without using a liquid culture containing glucose at a high concentration. In the present invention, moreover, brown adipocytes were successfully formed from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail, etc. The supernatant of brown adipocytes according to the present invention is expected as applicable to the development of therapeutic drugs for sugar metabolism-related diseases and cosmetics.

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and / or uncoupling protein 1 (Thermogenin / Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

The invention discloses a composition for reducing body fat rate and body fat rebound and its preparation method and application. The composition comprises the following components in parts by weight: 0.5-10 parts of plankton extract, 0.1-1 part of Irisin, 2-5 parts lotus (Nelumbonucifera) leaf extract, 1-6 parts caffeine, 1-4 parts hydrolyzed red algae extract, and 0.01-0.1 parts oligopeptide-1. The present invention mainly uses irisin, plankton extract and functional peptide as the core compatibility to induce energy-storing white adipocytes to transform into energy-consuming brown adipocytes, prevent fat from re-accumulating in the process of reducing fat and slimming, and reduce fat loss. After the rebound phenomenon, promote positive energy consumption, so as to achieve the purpose of efficient and healthy slimming. At the same time, the biological preparation of the present invention has a synergistic effect on sports slimming.

Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.

The purpose of the present invention is to provide: a novel hepatic fibrosis-inhibiting agent or brown fat cell-activating agent; and a drug for preventing and / or treating non-alcoholic fatty hepatitis and containing said agent as an active ingredient. The present invention pertains to: a hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin as an active ingredient; and a drug for preventing and / or treating non-alcoholic fatty hepatitis and containing taxifolin as an active ingredient.